Pathogenesis of Liver Fibrosis
The DOI matches its Crossref record; 220 of the 222 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Liver fibrosis is a major cause of morbidity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty liver disease associated with obesity. Hepatic stellate cell activation represents a critical event in fibrosis because these cells become the primary source of extracellular matrix in liver upon injury. Use of cell-culture and animal models has expanded our understanding of the mechanisms underlying stellate cell activation and has shed new light on genetic regulation, the contribution of immune signaling, and the potential reversibility of the disease. As pathways of fibrogenesis are increasingly clarified, the key challenge will be translating new advances into the development of antifibrotic therapies for patients with chronic liver disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3, a member of the STATs family, is a key transcriptional mediator of cellular processes [43, 44].”
From Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation (2025) · cites this paper as [43]
In the citing paper
“they may also derive from portal fibroblasts, bone marrow-derived cells, circulating fibrocytes, [7] and by the controversially discussed epithelial-tomesenchymal (EMT) [8,9] or endothelial-to-mesenchymal (EndoTM) transition.[10,11]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [7]
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Self-citationMany roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Bendelac, A., Savage, P. B., & Teyton, L. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141711 · Cited by 2,155
Research works printed but not linked: 15
- 10.1172/jci200112373 · DOI · Paper page
- 10.1055/s-2001-17556 · DOI · Paper page
- Stupack DG., 2007, Oncology, 21, 6
- Hehlgans S, 2007, Biochim. Biophys. Acta, 1775, 163
- Omenetti A, 2008, J. Clin. Investig., 118, 3331
- Pinzani M, 1996, Am. J. Pathol., 148, 785
- Sims DE., 1991, Can. J. Cardiol., 7, 431
- Thimgan MS, 1999, Am. J. Physiol., 277, G137
- 10.1136/gut.2005.088690 · DOI · Paper page
- Gao B., 2005, Cell Mol. Immunol., 2, 92
- Anania FA, 1995, Hepatology, 21, 1640
- Connolly MK, 2009, J. Clin. Investig., 119, 3213
- Seki E, 2009, J. Clin. Investig., 119, 1858
- McCrudden R, 2000, Histol. Histopathol., 15, 1159
- 10.1002/hep.23046 · DOI · Paper page
Cited by
Items 601–700 of 1,007
Reza, H. M., Tabassum, N., Sagor, M. A. T., Chowdhury, M. R. H., Rahman, M., Jain, P., & Alam, M. A. (2016) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2015.1124956 · Cited by 35
The impact of retinol loading and surface charge on the hepatic delivery of lipid nanoparticles
Pan, T., Wang, P., Hung, C., Aljuffali, I. A., Dai, Y.-S., & Fang, J. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.02.029 · Cited by 35
Protective Effects of Amarogentin against Carbon Tetrachloride-Induced Liver Fibrosis in Mice
Zhang, Y. P., Zhao, H., Li, H., Cao, W., Wang, F., Zhang, T., & Wang, S. (2017) · Molecules · doi:10.3390/molecules22050754 · Cited by 35
“Upon injury, quiescent HSCs transform into the proliferative and α-SMA-expressing myofibroblast phenotype that synthesizes ECM proteins [32,33].”
BackgroundNrf2 activation is required for curcumin to induce lipocyte phenotype in hepatic stellate cells
Lu, C., Xu, W., & Zheng, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.037 · Cited by 35
Zhu, J., Wang, R., Xu, T., Zhang, S., Zhao, Y., Li, Z., Wang, C., Zhou, J., Gao, D., Hu, Y. W., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01277 · Cited by 35
“Liver fibrosis is a leading cause of liver health problems worldwide because of viral infection, alcoholism, chemical toxicity or metabolic and biliary disorders (Hernandez-Gea and Friedman, 2011; Sant’Anna et al., 2011).”
BackgroundTian, H., Liu, L., Li, Z., Liu, W., Sun, Z., Xu, Y., Wang, S., Liang, C., Hai, Y., Feng, Q., et al. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.11.027 · Cited by 35
Cops, J., Müllens, W., Verbrugge, F. H., Swennen, Q., Moor, B. D., Reynders, C., Penders, J., Achten, R., Driessen, A. L. C., Dendooven, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36189-3 · Cited by 35
Li, X., Zhang, H., Pan, L., Zou, H., Miao, X., Cheng, J., & Wu, Y. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7534 · Cited by 35
Brougham‐Cook, A., Jain, I., Kukla, D. A., Masood, F., Kimmel, H., Ryoo, H., Khetani, S. R., & Underhill, G. H. (2021) · SSRN Electronic Journal · doi:10.1016/j.actbio.2021.11.015 · Cited by 35
Zhu, X., Ye, S., Yu, D., Zhang, Y., Li, J., Zhang, M., Leng, Y., Yang, T., Luo, J., Chen, X., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15490 · Cited by 34
“Thus, potential therapies for these pathologies should ideally possess proregenerative and anti-fibrotic properties, for example, the ability to control hepatocyte proliferation and inactivate activated HSCs (Hernandez-Gea & Friedman, 2011).”
BackgroundSaber, S., Mahmoud, A. A. A., Helal, N. S., El-Ahwany, E. G., & Abdel-Ghany, R. H. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2017-0728 · Cited by 34
Yue, Z., Jiang, Z., Ruan, B., Duan, J., Song, P., Liu, J., Han, H., & Wang, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60056 · Cited by 34
Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment
Xiong, Y., & Huang, J. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00489-0 · Cited by 34
Chen, X., Wang, Z., Han, S., Wang, Z., Zhang, Y., Li, X., Xia, N. L., Yu, W., Jia, C., Ni, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04403-2 · Cited by 35
“It is a key step in the development of various chronic liver diseases to cirrhosis and an important link that affects the prognosis of chronic liver disease [1, 27].”
BackgroundSomade, O. T., Adeyi, O. E., Ajayi, B. O., Asunde, O. O., Iloh, P. D., Adesanya, A. A., Babalola, O. I., Folorunsho, O. T., Olakunle, D. A., & Lawal, O. F. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100179 · Cited by 35
“Fibrosis, a disorder marked by the scarring and thickening of connective tissue due to aggregation of extracellular matrix proteins, is commonly related with chronic tissue inflammation [7].”
BackgroundRole of NLRC5 in progression and reversal of hepatic fibrosis
Liu, X., Wu, Y., Yang, Y., Li, W., Huang, C., Meng, X., & Li, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.01.012 · Cited by 34
Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR‐S1PR2 ‐dependent mechanism
Xu, W., Lu, C., Zhang, F., Shao, J., & Zheng, S. (2016) · IUBMB Life · doi:10.1002/iub.1492 · Cited by 34
Bae, J.-S., Park, J. M., Lee, J., Oh, B., Jang, S., Lee, Y. B., Han, Y.-M., Ock, C.-Y., Cha, J.-Y., & Hahm, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.10.002 · Cited by 34
Lu, C., Xu, W., Shao, J., Zhang, F., Chen, A., & Zheng, S. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.06.001 · Cited by 34
Miao, Y., Wu, Y., Jin, Y.-J., Lei, M., Nan, J., & Wu, X. Z. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.108945 · Cited by 34
Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ
Liu, F., Li, S., Chen, P., Gu, Y., Wang, S., Wang, L., Chen, C., Wang, R., & Yuan, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110550 · Cited by 33
Liu, M., Gu, Y., Nie, W., Zhu, X., Qi, M., Zhao, R., Zhu, W., & Zhang, X. (2024) · Phytotherapy Research · doi:10.1002/ptr.8338 · Cited by 33
AI‐Assisted Drug Re‐Purposing for Human Liver Fibrosis
Guan, Y., Cui, L., Inchai, J., Fang, Z., Law, J., Brito, A. A. G., Pawlosky, A., Gottweis, J., Daryin, A., Myaskovsky, A., et al. (2025) · Advanced Science · doi:10.1002/advs.202508751 · Cited by 33
A New Oleanolic Acid Derivative against CCl4-Induced Hepatic Fibrosis in Rats
Xiang, H., Han, Y., Zhang, Y., Yan, W., Xu, B., Chu, F., Xie, T., Jia, M., Yan, M., Zhao, R., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030553 · Cited by 33
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis
Zhang, T., Zhang, N., Xing, J., Zhang, S., Chen, Y., Xu, D., & Gu, J. (2023) · Nature Communications · doi:10.1038/s41467-023-38371-2 · Cited by 33
The multifaceted role of macrophages during acute liver injury
Hassan, G. S., Molina, M. F., & Shoukry, N. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237042 · Cited by 33
“Sinusoidal blood harbors immune cells capable of identifying and clearing pathogens, toxins, and cellular debris originating from the portal or systemic circulation (2).”
Sun, B., Zhang, X., Cheng, X., Zhang, Y., Chen, L., Shi, L., Liu, Z., Qian, H., Wu, M., & Yin, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080212 · Cited by 33
Pan, T., & Wang, P. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/734987 · Cited by 33
Yang, Y., Yang, F., Wu, X., Lv, X., & Li, J. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0437 · Cited by 33
“Many studies have demonstrated that acetaldehyde stimulates the deposition of extracellular matrix (ECM) by activating the hepatic stellate cells (HSCs), themajor cell type involved in ALF (Friedman 1999; Hernandez-Gea and Friedman 2011; Mello et al. 2008).”
BackgroundEl-Ahwany, E. G., Nagy, F., Zoheiry, M. K., Shemis, M. A., Nosseir, M. M. F., Abu-Taleb, H. M., El-Ghannam, M., Atta, R., & Zada, S. K. (2016) · Electronic physician · doi:10.19082/1804 · Cited by 33
Chen, J., Pan, J., Wang, J., Song, K., Zhu, D., Huang, C., & Duan, Y. (2016) · Scientific Reports · doi:10.1038/srep30957 · Cited by 33
Anatomy, pathophysiology and basic mechanisms of disease
Crawford, J. M., & Burt, A. D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00001-5 · Cited by 34
Chen, P., Li, J., Huo, Y., Lu, J., Wan, L., Yang, Q., Huang, J., Gan, R., & Guo, C. (2016) · Scientific Reports · doi:10.1038/srep33593 · Cited by 33
Virologic and immunologic aspects of HIV–hepatitis C virus coinfection
Chew, K. W., & Bhattacharya, D. (2016) · AIDS · doi:10.1097/qad.0000000000001203 · Cited by 33
miR-706 inhibits the oxidative stress-induced activation of PKCα/TAOK1 in liver fibrogenesis
Yin, R., Guo, D., Zhang, S., & Zhang, X. (2016) · Scientific Reports · doi:10.1038/srep37509 · Cited by 33
Hepcidin in morbidly obese women with non-alcoholic fatty liver disease
Auguet, T., Aragonès, G., Berlanga, A., Martínez, S., Sabench, F., Binetti, J., Aguilar, C., Porras, J. A., López, A. M., Castillo, D. D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187065 · Cited by 33
Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment
Manka, P. P., Coombes, J. D., Boosman, R. J., Gauthier, K. C., Papa, S., & Syn, W. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.055 · Cited by 33
Sequera, C., Manzano, S., Guerrero, C., & Porrás, A. (2018) · Hepatic Oncology · doi:10.2217/hep-2017-0026 · Cited by 33
Lin, N., Meng, L., Lin, J., Chen, S., Zhang, P., Chen, Q., & Lin, Y. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29380 · Cited by 33
“viral infection, HSCs transform from quiescent cells into activated myofibroblast‐like cells,(31) which can express fibrinogen, inflammatory factors, and other mediators that lead to the development of hepatic fibrosis.(32,33) Furthermore, a previous study also demonstrated that aHSCs could promote the development of…”
BackgroundmTOR Overactivation in Mesenchymal cells Aggravates CCl4− Induced liver Fibrosis
Shan, L., Ding, Y., Fu, Y., Zhou, L., Dong, X., Chen, S., Wu, H., Nai, W., Zheng, H., Xu, W., et al. (2016) · Scientific Reports · doi:10.1038/srep36037 · Cited by 33
Tang, S., Gao, J., Wen, S., Tong, H., Yan, Z., Liu, R., & Tang, C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6161 · Cited by 32
Chen, J. Y., Newcomb, B., Zhou, C., Pondick, J. V., Ghoshal, S., York, S. R., Motola, D., Coant, N., Yi, J. K., Mao, C., et al. (2017) · Scientific Reports · doi:10.1038/srep44867 · Cited by 32
Periostin in chronic liver diseases: Current research and future perspectives
Jia, Y., Zhong, F., Jiang, S., Guo, Q., Jin, H., Wang, F., Li, M., Wang, L., Chen, A., Zhang, F., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.021 · Cited by 32
Yang, Y., Bu, F., Yang, Y., Li, H., Huang, C., Meng, X., Zhang, L., Lv, X., & Li, J. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.07.012 · Cited by 32
Dai, C., Yusuf, A., Sun, H. M., Shu, G., & Deng, X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153746 · Cited by 32
Zhao, J., Li, R., Li, J., Chen, Z., Lin, Z., Zhang, B., Deng, L., Chen, G., & Wang, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03689-w · Cited by 32
“[25]; Studies have shown that genes in paracancerous tissues can determine the survival rate of HCC patients rather than genes in cancer tissues, which shows that the TME plays an important role in HCC development and metastasis.”
BackgroundKim, J. H., Lee, C. H., & Lee, S. (2016) · The Journal of Microbiology · doi:10.1007/s12275-016-6240-3 · Cited by 32
Amygdalin inhibits HSC-T6 cell proliferation and fibrosis through the regulation of TGF-β/CTGF
Luo, H., Li, L., Tang, J., Zhang, F., Zhao, F., Sun, D., Zheng, F., & Wang, X. (2016) · Molecular & Cellular Toxicology · doi:10.1007/s13273-016-0031-0 · Cited by 32
Li, W., Chen, X., Yang, Y., Huang, H., Li, H.-D., Huang, C., Meng, X., & Li, J. (2016) · Toxicology · doi:10.1016/j.tox.2016.11.004 · Cited by 32
Lao, Y., Li, Y., Zhang, P., Shao, Q., Lin, W., Qiu, B., Lv, Y., Tang, L., Su, S., Zhang, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.016 · Cited by 32
“Recently, increasing evidence has indicated that fibroblast-like cells, which are features of liver fibrosis, are mainly derived from activated hepatic stellate cells (HSCs); therefore, HSC activation is considered a pivotal event leading to fibrosis.(1,4) This process is tightly modulated by dynamic interactions betw…”
BackgroundPeng, Y., Li, L., Zhang, X., Xie, M., Yang, C., Tu, S., Shen, H., Hu, G., Tao, L., & Yang, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7548 · Cited by 32
Borkham‐Kamphorst, E., Zimmermann, H. W., Gaßler, N., Bissels, U., Bosio, A., Tacke, F., Weiskirchen, R., & Kanse, S. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.007 · Cited by 32
“This state is initiated by diverse factors that include damage to parenchymal cells, hepatocytes, due to pathogens, alcoholism, toxins, and/or fatty diet [1].”
BackgroundGlucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism
Zhang, L., Yao, W., Xia, J., Wang, T., & Huang, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081885 · Cited by 32
“Abbreviations AA Amino acids AC Adenylate cyclase AFABP Adipocyte fatty acid binding protein AMPK AMP-activated protein kinase cAMP Cyclic AMP CMA Chaperone-mediated autophagy COP1 Constitutively photomorphogenic 1 CPS1 Carbamoyl phosphate synthetase 1 CPT1A Carnitine palmitoyltransferase 1A CR Caloric restriction CRE…”
BackgroundInfluentialLee, J. H., Seo, K. H., Yang, J. H., Cho, S. S., Kim, N. Y., Kim, J. H., Kim, K. M., & Ki, S. H. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.10.259 · Cited by 31
Nie, Y., Zhou, W., Niu, T., Mao, M., Zhan, Y., Li, Y., Wang, K., Li, M., & Ding, K. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01454-x · Cited by 31
Targeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer
Hah, N., Sherman, M. H., Yu, R. T., Downes, M., & Evans, R. M. (2015) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2015.80.027185 · Cited by 31
MiR-29a and miR-652 Attenuate Liver Fibrosis by Inhibiting the Differentiation of CD4+ T Cells
Xuan, J., Guo, S., Huang, A., Xu, H.-B., Shao, M., Yang, Y., & Wen, W. (2017) · Cell Structure and Function · doi:10.1247/csf.17005 · Cited by 31
Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
Petrizzo, A., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., Tagliamonte, M., & Buonaguro, L. (2018) · Infectious Agents and Cancer · doi:10.1186/s13027-018-0183-8 · Cited by 31
Hu, X., & Zhou, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173424 · Cited by 31
Tang, X., Melis, M., Lu, C., Rappa, A., Zhang, T., Jessurun, J., Gross, S. S., & Gudas, L. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101331 · Cited by 31
“models (32), the methionine–choline-deficient (MCD) model of NASH (33), and the CCl4 model of fibrogenesis (34).”
Chen, H.-J., Liang, T.-M., Lee, I., Huang, Y., & Lin, Y. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.08.049 · Cited by 31
Yu, F., Zheng, Y., Hong, W., Chen, B., Dong, P., & Zheng, J. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4452 · Cited by 31
Lv, P.-Y., Feng, H., Huang, W., Tian, Y., Wang, Y., Qin, Y., Li, X., Hu, K., Zhou, H., & Ouyang, D. (2017) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2017.02.012 · Cited by 31
Gong, J., Han, J., He, J., Liu, J., Han, P., Wang, Y., Li, M., Li, D., Ding, X., Du, Z., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.65 · Cited by 31
Lim, B. J., Lee, W.-K., Lee, H. W., Lee, K. S., Kim, J. K., Chang, H. Y., & Lee, J. I. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0306-2 · Cited by 31
Sun, B., Liang, Z., Wang, Y., Yu, Y., Zhou, X., Geng, X., & Li, B. (2024) · Toxicology · doi:10.1016/j.tox.2024.153829 · Cited by 30
Zarzour, R. A., Alshawsh, M. A., Asif, M., Al‐Mansoub, M. A., Mohamed, Z., Ahmad, M., Majid, A. M. S. A., Asmawi, M. Z., Kaur, G., Al-dualimi, D. W., et al. (2018) · Nutrients · doi:10.3390/nu10081057 · Cited by 31
“It inhibits fibrosis by suppressing proliferation and migration of the hepatic stellate cells (HSC) and attenuating gene expression of transforming growth factor beta 1 (TGF-β1) [27].”
BackgroundChoi, S., Jung, H. J., Kim, M. W., Kang, J., Shin, D., Jang, Y., Yoon, Y. S., & Oh, S. H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.156 · Cited by 30
Zhou, Y., Wu, R., Cai, F., Zhou, W., Lu, Y.-Y., Zhang, H., Chen, Q., Sun, M., & Su, S.-B. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1999275 · Cited by 30
“It reflects an imbalance between fibrosis progression and regression [5] and confers a significant risk for morbidity and mortality [21].”
Carson, J. P., Robinson, M. W., Ramm, G. A., & Gobert, G. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06774-3 · Cited by 32
Zhan, J., Cao, H., Hu, T., Shen, J., Wang, W., Wu, P., Yang, G., Ho, C., & Li, S. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c01851 · Cited by 30
Shuai, C., Xia, G., Yuan, F., Wang, S., & Lv, X. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174198 · Cited by 30
Mastoridou, E. M., GOUSSIA, A. C., Glantzounis, G. K., Kanavaros, P., & Charchanti, A. V. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.801340 · Cited by 31
“On the other hand, autophagy-deficient qHSCs may be unable to degrade lipid droplets (LDs), resulting in decreased free fatty acids (FFA) availability and ATP production (Hernandez-Gea and Friedman, 2011).”
BackgroundGomisin D alleviates liver fibrosis through targeting PDGFRβ in hepatic stellate cells
Wang, R., Liu, F., Chen, P., Li, S., Gu, Y., Wang, L., Chen, C., & Yuan, Y. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123639 · Cited by 30
Jiang, Y., Hou, L., Dou, J., Xuan, M., Cui, Z., Lian, L., Nan, J., & Wu, Y. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155145 · Cited by 30
Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B
Chen, Y., Peng, J., & Hou, J. (2013) · Hepatology International · doi:10.1007/s12072-013-9439-y · Cited by 30
“F o rn s In d ex [1 7 ] H C V 2 0 0 2 7 .”
BackgroundInfluentialTargeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis
Khaja, F., Jayawardena, D., Kuzmis, A., & Önyüksel, H. (2016) · Nanomaterials · doi:10.3390/nano6010008 · Cited by 30
New role and molecular mechanism of Gadd45a in hepatic fibrosis
Liang, H., Sun, Q., Xu, T., Wu, Y., Zhang, H., Fu, R., Cai, F., Zhou, Q., Zhou, K., Du, Q.-W., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i9.2779 · Cited by 30
Ceni, E., Mello, T., Polvani, S., Vasseur-Cognet, M., Tarocchi, M., Tempesti, S., Cavalieri, D., Beltrame, L., Marroncini, G., Pinzani, M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.003 · Cited by 30
Kerola, A., Lampela, H., Lohi, J., Heikkilä, P., Mutanen, A., Jalanko, H., & Pakarinen, M. P. (2017) · Surgery · doi:10.1016/j.surg.2017.04.013 · Cited by 30
“During cholestasis activated HSCs encircle bile ducts, and periductular myofibroblasts form portal-to-portal fibrotic septa.(12,27) In BA, biliary epithelial cells and cells adjacent to ductal reactions express mesenchymal markers and growth factors consistent with active collagen synthesis, although the origin of the…”
BackgroundMultifunctional YY1 in Liver Diseases
Yang, S., Zhou, J., Gao, W., Yang, X., Yang, D., Tian, Z., Wu, Y., Zhang, M., Zhang, Y., & Ni, B. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1607451 · Cited by 30
Axley, P. D., Mudumbi, S. K., Sarker, S., Kuo, Y., & Singal, A. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197117 · Cited by 30
Xia, P., He, H., Kristine, M. S., Guan, W., Gao, J., Wang, Z., Hu, J., Han, L., Li, J., Han, W., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.030 · Cited by 30
Sharma, A., Verma, A. K., Kofron, M. J., Kudira, R., Miethke, A. G., Wu, T., Wang, J., & Gandhi, C. R. (2020) · Hepatology · doi:10.1002/hep.31188 · Cited by 30
“Consistent with previous reports,(1,2,4,6) expression of proinflammatory tumor necrosis factor (TNF)α, IL6, and C-X-C motif chemokine ligand 1 (CXCL1) was strongly increased in aHSCs compared to qHSCs, in contrast to unaltered expression of anti-inflammatory IL10 (Supporting Fig.”
BackgroundResultInfluentialSalvianolic acid B blocks hepatic stellate cell activation via FGF19/FGFR4 signaling
Shuxia, T., Chen, M., Wang, B., Han, Y., Shang, H., & Chen, J. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.07.013 · Cited by 30
Pascut, D., Hoang, M., Nguyễn, N. N. Q., Pratama, M. Y., & Tiribelli, C. (2021) · Cancers · doi:10.3390/cancers13102485 · Cited by 30
“The SREBP family of proteins, such as SREBP1a, SREBP1c, and SREBP2, are major regulators of lipid metabolism [68,69] with SREBP2 specifically regulating cholesterol homeostasis [70,71].”
BackgroundLiver regeneration and tumour stimulation: implications of the renin-angiotensin system
Koh, S. L., Ager, E. I., & Christophi, C. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02306.x · Cited by 30
Chan, J., Sharkey, F. E., Kushwaha, R. S., VandeBerg, J. F., & VandeBerg, J. L. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00415.2011 · Cited by 30
Li, Y., Lua, I., French, S. W., & Asahina, K. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00257.2015 · Cited by 30
Zhu, H., Zhao, H., Xu, S., Zhang, Y., Ding, Y., Li, J., Huang, C., & Ma, T. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105926 · Cited by 29
Cannabidiol markedly alleviates skin and liver fibrosis
del Río, C., Ruíz-Pino, F., Prados, M. E., Fiebich, B. L., Tena‐Sempere, M., & Muñóz, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981817 · Cited by 29
“Liver disease progression by sustained inflammation and progressive fibrosis leads to cirrhosis, a major cause of morbidity and mortality worldwide (Hernandez-Gea and Friedman, 2011).”
BackgroundTang, Y., Hu, C., & Liu, Y. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.03.067 · Cited by 29
Hasan, I. H., El-Desouky, M. A., Hozayen, W. G., & Aziz, G. M. A. E. –. (2015) · Pharmacology · doi:10.1159/000441229 · Cited by 29
Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background
Chung, S. I., Moon, H., Kim, D. Y., Cho, K. J., Ju, H.-L., Kim, D. Y., Ahn, S. H., Han, K., & Ro, S. W. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0423-6 · Cited by 30
Shear wave elastography results correlate with liver fibrosis histology and liver function reserve
Feng, Y.-H., Hu, X.-D., Zhai, L., Liu, J., Qiu, L., Zu, Y., Liang, S., Gui, Y., & Qian, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i17.4338 · Cited by 29
Building discontinuous liver sinusoidal vessels
Griffin, C. T., & Gao, S. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92823 · Cited by 29
Zhao, Z., Liu, H., Sun, X., Guo, T., Shen, L., Tao, Y., & Liu, C. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217701005 · Cited by 29
“Liver fibrosis commonly occurs in various chronic liver diseases and may advance to end-stage liver disease, cirrhosis, and even hepatocellular carcinoma.(1) Hepatic stellate cell (HSC) activation plays a key role in liver fibrosis and contributes to overdeposition of the extracellular matrix (ECM).”
BackgroundStructure, Function, and Responses to Injury
Crawford, J. M., Bioulac‐Sage, P., & Hytiroglou, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00001-7 · Cited by 29
Bu, F., Chen, Y., Yu, H., Chen, X., Yang, Y., Pan, X., Wang, Q., Wu, Y., Huang, C., Meng, X., et al. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.03.010 · Cited by 29
Xing, X., Chen, S., Li, L., Cao, Y., Chen, L., Wang, X., & Zhu, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00525 · Cited by 29
Metadata
- Authors
- Hernandez-Gea, V., & Friedman, S. L.
- Affiliations
- Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029;
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Friedman, Scott L.
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2011-02-28
- Volume
- 6
- Issue
- 1
- Pages
- 425-456
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2142988890
- Cited by
- 1,809
- References
- 220
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 121 · 2023: 112 · 2022: 148 · 2021: 174 · 2020: 145 · 2019: 119 · 2018: 117 · 2017: 131 · 2016: 136 · 2015: 124 · 2014: 97 · 2013: 76 · 2012: 67
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Pathology Mechanisms of Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cell activation, extracellular matrix, chronic viral hepatitis, hepatic steatosis, obesity, immune signaling, genetic control, fibrosis reversibility, antifibrotic therapy, chronic liver disease
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.